NewAmsterdam Pharma (NAMS) Cash per Single Share

Symbol and logo of brand NewAmsterdam Pharma Corp (NAMS)

NewAmsterdam Pharma focuses on cardiology biotech, awaiting obicetrapib test results for the non-statin patient market. Cash per share currently reflects liquidity dynamics, where 5.27 represents the current metric level. Successful research maintains a strong staff of regulatory experts. The delivery safety of metabolic drugs is ensured by a costly but reliable cold chain.

NewAmsterdam Pharma - NAMS Cash per Share (period 06/21/2023 - 11/20/2026)

Comprehensive metric breakdowns and analytics for newamsterdampharma.com (NAMS)

- market value and analyst target forecast:
- cash and cash flow data:
Comprehensive company analysis:NAMS NewAmsterdam Pharma Corp
Signature product of NewAmsterdam Pharma

NewAmsterdam Pharma (NAMS) is diversifying its scientific risks by developing affordable medications to combat cholesterol and prevent cardiovascular pathologies. This metric reflects the proportion of liquid assets per share, allowing for an assessment of the internal financial reserve for expansion or the risk of management stagnation, which is clearly interpreted through the current cash per share level.